List of accesskeys skip navigation

Dr Tong Kian Ti, Aaron

Consultant

Department of Nuclear Medicine & PET

MBBS, MRCP(UK), MMed (Int Med), FAMS

Dr Tong graduated with MBBS from the National University of Singapore in 2005. He obtained his Membership of the Royal College of Physicians (UK) in 2010. He completed his senior residency training in Nuclear Medicine and PET (Singapore).

His clinical interests include cardiovascular imaging, oncologic and non -oncologic applications of PET, SPECT/CT as well as radionuclide therapy.

EDUCATION

  • MBBS, National University of Singapore 2005
  • Membership of the Royal College of Physicians, MRCP (UK) 2010
  • Masters of Medicine, MMed (Internal Medicine) (Singapore) 2011
  • Fellow of the Academy of Medicine Singapore, FAMS 2015

PROFESSIONAL APPOINTMENTS & COMMITTEE MEMBERSHIPS

  • Committee member, Chapter of Nuclear Physicians, Academy of Medicine Singapore (2015 – present)
  • Physician Faculty for Nuclear Medicine Senior Residency (Singapore)
  • Physician Faculty for Diagnostic Radiology Residency (Singapore)

AWARDS

  • RSNA Travel Award for Young Investigators in Molecular Imaging 2013
  • TE-IQC Assessment by Singapore Productivity Association 2016 – Silver Award

PUBLICATIONS AND RESEARCH/TRIALS

  1. Thang SP, Tong AK, Lam WW, Ng DC. SPECT/CT in Musculoskeletal Infections. Semin Musculoskelet Radiol. 2014 Apr;18(2):194-202.
  2. Tong AK, Mann KP, Schuster DM, Yan X. A rare presentation of myocardial plasmacytoma assessed by FDG PET/CT. Clin Nucl Med. 2014 Jul;39(7):643-5.
  3. Tong AK, Tan SY, Go YY, Lam WW. Cardiac structural abnormalities associated with IgG4-related coronary periarteritis and inflammation revealed by multimodality imaging. Can J Cardiol. 2014 Aug;30(8):956.e15-7.
  4. Thang SP, Tong AK, Ng DC. Postmastectomy / Axillary node dissection chyloma: The additional value of SPECT/CT lymphoscintigraphy. J Breast Cancer. 2014 Sep;17(3):291-4.
  5. Khor LK, Loi HY, Sinha AK, Tong KT, Goh BC, Loh KS, Lu SJ.Correlation between 68Ga-DOTA-NOC PET/CT and 18F-FDG PET/CT in EBV-positive undifferentiated nasopharyngeal carcinoma. Eur J Nucl Med Mol Imaging. 2015 June;42(7):1162-3.
  6. Tong AK, Neo HS, Kok TY. Disseminated lymphoma evolving into Neurolymphomatosis during Mid-cycle of chemotherapy detected by 18F FDG PET/CT. Ann Acad Med Singapore. 2015 Nov;44(11):545-7.
  7. Khor LK, Loi HY, Sinha AK, Tong KT, Goh BC, Loh KS, Lu SJ.  68Ga-DOTA-peptide: A novel molecular biomarker for nasopharyngeal carcinoma. Head Neck. 2016 Apr;38(4):E76-80.
  8. Rodríguez LS, Thang SP, Li H, Khor LK, Tay YS, Myint KO, Tong AK. A descriptive analysis of remnant activity during 90Y resin microspheres radioembolization of hepatic tumours: technical and dosimetric implications. Ann Nucl Med. 2016 Apr;30(3):255-261.
  9. Tong AK, Zhang ZX, Zaheer S, Yan XS. Dual phase 18F-fluorocholine PET/CT to detect locoregional recurrence of prostate cancer: comparison between each time point of imaging and a summation scan. Clin Imag. 2016 May-Jun;40(3):486-491.
  10. Tong AK, Kao YH, Too CW, Chin KF, Ng DC, Chow PK. Yttrium-90 hepatic radioembolization: Clinical review and current techniques in interventional radiology and personalized dosimetry. Br J Radiol. 2016 Jun;89(1062):20150943.

Clinical trials

  1. Co-Investigator: “Determining the feasibility of Peptide Receptor Radionuclide Therapy by means of Gallium 68 DOTAPEPTDE PET/ CT Imaging in non-radioiodine-avid differentiated thyroid carcinoma patients” by SingHealth Foundation, Singapore. Clinical Research Start-Up Grant category (S$49,545.40).
  2. Co-Investigator: “Somatostatin receptor imaging in Nasopharyngeal cancer” by NCC Research Fund 2015 (S$49,500.00).
  3. Principal Investigator: “Functional imaging with Gallium-68 DOTAPEPTDE PET/CT and 131I-metaiodobenzylguanidine (MIBG) in order to determine feasibility of  Peptide Receptor Radionuclide Therapy and MIBG therapy (combined therapy)  in neuroblastoma” by SingHealth Foundation, Singapore. Clinical Research Start-up Grant category ($24,000).
  4. Co-Investigator: “18F-MISO PET guided dose escalation in nasopharyngeal carcinoma – a feasibility and planning study” sponsored by Terry Fox Foundation ($69,000).

Last Modified Date :04 Jan 2010